IP Library › Granted Patent US 10,961,516
Granted Patent B2
US 10,961,516 · App. 16/344,779 · Granted Mar 30, 2021

Proline hydroxylase and uses thereof

Inventors: Hao Hong (Tianjin, CN); Gage James (Tianjin, CN); Jiangping Lu (Tianjin, CN); Na Zhang (Tianjin, CN); Wenyan Yu (Tianjin, CN); Fang Liu (Tianjin, CN); Yanjun Li (Tianjin, CN); Xin Huang (Tianjin, CN); Juan Gao (Tianjin, CN); Kejian Zhang (Tianjin, CN); Yulei Ma (Tianjin, CN); Junlu Wei (Tianjin, CN)
Assignees: ASYMCHEM LABORATORIES (TIANJIN) CO., LTD.; ASYMCHEM LIFE SCIENCES (TIANJIN) CO., LTD.; TIANJIN ASYMCHEM PHARMACEUTICALS CO., LTD.; ASYMCHEM LABORATORIES (FUXIN) CO., LTD.; JILIN ASYMCHEM LABORATORIES CO., LTD.
C12N9/0071C12N15/70C12N15/81C12Y114/11002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,961,516
App. No.
16/344,779
Granted
Mar 30, 2021
Kind
B2
Abstract

Provided are a proline hydroxylase and uses thereof. The proline hydroxylase comprises (a) a protein having the amino acid sequence as shown in SEQ ID NO: 2; (b) a protein having an amino acid sequence of SEQ HD NO: 2 with a mutation of one or more amino acids and having a proline hydroxylase activity; or (c) a protein retaining the mutation of one or more amino acids as in (b), and having the proline hydroxylase activity and having at least 78% homology with the amino acid sequence of the protein in (b). Protein having the amino acid sequence as shown in SEQ HD NO: 2 and mutants obtained by genetically engineering have higher catalytic specificity or significantly increased catalytic activity when compared to proline hydroxylases in prior art.

Claims (9)

1. A proline hydroxylase, comprising a protein having the amino acid sequence of SEQ ID NO: 2 with the exception of a mutation of one or more amino acids, wherein the mutation of one or more amino acids must comprise I39, wherein the mutation of I39 is I39K or I39R, and the mutation of one or more amino acids is selected from the group consisting of: H14R, L16N, T25R, F26L, E27K, D30S, S33N, E34N, E34G, E34L, E34S, E34D, Y35W, Y35K, S37W, S37F, S37E, S37N, S37T, S37C, W40F, K41E, D54G, H55Q, S57L, I58T, I58Y, I58A, I58R, I58V, I58S, I58C, K86P, T91A, F95Y, C97Y, I98V, K106V, K106T, K106Q, F111S, K112E, K112R, S154A, K162E, L166M, I118F, I118V, I118R, H119R, H119F, I120V, K123D, K123N, K123Q, K123S, K123I, K123T, T130N, D134G, V135K, N165H, D173G, K209R, I223V and S225A and having proline hydroxylase activity.

2. The proline hydroxylase of claim 1 , wherein the mutation comprises any one of the combinations selected from the group consisting of:

E27K+I39K/R, I39K/R+Y35W/K, I39K/R+K123D/1/Q/S, I39K/R+N165H, E27K+I39K/R+K123D/I/Q/S, E27K+Y35W/K+I39K/R, E27K+S37C/E/F/N/W/T+I39K/R, E27K+E34N/G/L/D/S+I39K/R, E27K+I39K/R+D30S, E27K+I39K/R+I118F/V/R, E27K+I39K/R+I98V, E27K+I39K+Y35W/K+S37C/E/F/N/W/T, E27K+I39K/R+S37C/E/F/N/W/T+K123D/I/Q/S, E27K+I39K/R+K106Q+K112E, E27K+I39K/R+Y35W/K+S37C/E/F/N/W/T+K123D/I/Q/S, E27K+I39K /R+S37C/E/F/N/W/T+I58A/C/R/S/T/V/Y, S37C/E/F/N/W/T+I39K/R+I223V+K123D/I/Q/S, E27K+S 37C/E/F/N/W/T+I39K/R+K123D/I/Q/S+I98V, E27K+S37C/E/F/N/W/T+I39K/R+K123D/I/Q/S+I223V, F26L+E27K+I39K/R+K123D/I/Q/S, 1223V+S37C/E/F/N/W/T+E27K+I39K/R, E27K+S37C/E/F/N/W/T+I39K/R+I98V+K123D/I/Q/S+I223V,E27K+S37C/E/F/N/W/T +I39K/R+I58A/C/R/S/T/V/Y+K123D/I/Q/S, E27K+I39K/R+K123D/I/Q/S+N165H, T25G/R+E27K+S37C/E/F/N/W/T+I39K/R+I58A/C/R/S/T/V/Y, E27K+S37C/E/F/N/W/T+I39K/R+I58A/C/R/S/T/V/Y+K86P, E27K+D30S+I39K/R+I58A/C/R/S/T/V/Y+K112E, S37C/E/F/N/W/T+I39K/R+N165H, E27K+E34N/G/L/D/S+I39K/R+158 A/C/R/S/T/V/Y+I223V, E27K+S37C/E/F/N/W/T+I39K/R+158A/C/R/S/T/V/Y+D173G, E27K+S37C/E/F/N/W/T+I39K/R+I58A/C/R/S/T/V/Y+D173G+I118F/V/R, E27K+E34N/G/L/D/S+S3 7C/E/F/N/W/T+I39K/R+I58A/C/R/S/T/V/Y, E27K+E34N/G/L/D/S+S37C/E/F/N/W/T+I39K/R+I58A /C/R/S/T/V/Y+D173G, E27K+S37C/E/F/N/W/T+I39K/R+I58A/C/R/S/T/V/Y+D173G+K123D/I/Q/S, E27K+S37C/E/F/N/W/T+I39K/R+I58A/C/R/S/T/V/Y+D173G+K123D/I/Q/S+I118F/V/R, E27K+S37C /E/F/N/W/T+I39K/R+I58A/C/R/S/T/V/Y+D173G+K123D/I/Q/S+N165H, E27K+E34N/G/L/D/S+S37 C/E/F/N/W/T+I39K/R+I58A/C/R/S/T/V/+D173G+K123D/I/Q/S, H14R+E27K+D30S+E34N/G/L/D/S+I39K/R+I98V+K106V/T/Q+K112E/R+I223V, T25G/R+E27K+S37C/E/F/N/W/T+I39K/R+I58A/C/R/S/TA//Y+D173G+K123D/I/Q/S+I118F/V/R+N 165H, H14R+E27K+E34N/G/L/D/S+I39K/R+I98V+K106V/T/Q+K112E/R+I223V, H14R+E27K+E34N/G/L/D/S+S37C/E/F/N/W/T+I39K/R+I98V+K106V/T/Q+K112E/R+I223V, H14R+E27K+E34N/G/L/D/S+Y35W/K+I39K/R+I98V+K106V/T/Q+K112E/R+I223V, H14R+E27K+E34N/G/L/D/S+I39K/R+I98V+K106V/T/Q+K112E/R+K123D/I/Q/S+I223V,H14R+E27 K+E34N/G/L/D+I39K/R+I58A/C/R/S/T/V/Y+I98V+K106V/T/Q+K112E/R+I223V and H14R+E27K+E34N/G/L/D/S+I39K/R+I98V+K106V/T/Q+K112E/R+I118F/V/R+I223V, wherein ‘/’ represents ‘or’.

3. A method for producing an L-hydroxyproline derivative, wherein the method comprises:

contacting an L-proline derivative substrate with the proline hydroxylase of claim 1 to catalyze hydroxylation of the L-proline derivative substrate, to obtain the L-hydroxyproline derivative as shown in general formula (I):

wherein R 1 is selected from C 1 -C 5 alkylene or C 2 -C 5 alkenylene; R 2 is selected form C 0 -C 4 alkylene or C 2 -C 4 alkenylene; R 3 is selected from hydroxyl, amino, C 1 -C 6 alkoxy, aryloxy, C 1 -C 6 alkyl sulfenyl or C 1 -C 6 aryl sulfenyl; and R 4 is selected from hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl.

4. The method of claim 3 , wherein the method further comprises: adding a-oxoglutarate and O 2 as a common substrate and adding iron ions as a cofactor.

5. The method of claim 3 , wherein the L-hydroxyproline derivative is cis-4-hydroxy-L-proline or (2S,5S)-5-hydroxypiperidine-2-carboxylic acid.

6. The method of claim 3 , wherein the proline hydroxylase catalyzes hydroxylation of the L-proline derivative substrate in a temperature of 5-45° C.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2019
From: HONG, HAO; JAMES, GAGE; LU, JIANGPING; ZHANG, NA; YU, WENYAN; LIU, FANG; LI, YANJUN; HUANG, XIN; GAO, JUAN; ZHANG, KEJIAN; MA, YULEI; WEI, JUNLU
To: ASYMCHEM LABORATORIES (TIANJIN) CO., LTD.; ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTD.; TIANJIN ASYMCHEM PHARMACEUTICALS CO., LTD.; ASYMCHEM LABORATORIES (FUXIN) CO., LTD.; JILIN ASYMCHEM LABORATORIES CO., LTD.
Reel/Frame 048987/0732 →
Continuity (1)
Related Publication 20200199544A1 · Jun 25, 2020